AI-powered serum metabolomics analysis. Multi-biomarker risk assessment validated on 300 clinical samples. For research use only.
100-second overview of our Type 2 Diabetes risk assessment model
Rigorously validated with Leave-One-Out Cross-Validation (LOOCV) on 300 samples
Powered by our General Learning Encoder (GLE) — one foundational architecture for biomedical signals
Analyzes 1,291 metabolites simultaneously from LC-MS serum data. Detects patterns invisible to single-marker tests.
LOOCV validated on 300 clinical samples. Shuffle test confirms real signal, not artifacts. No data leakage.
Built on our General Learning Encoder — the transformer paradigm for biomedical signals. One architecture, multiple diseases.
This model is for research purposes only. Not FDA approved. Cannot diagnose diabetes. Requires laboratory LC-MS analysis.
Integration with your existing lab workflows. Structured risk reports from metabolomics data.
Early partners define how the world applies this technology. Collaborate on validation studies and publications.
Get API access to our T2D risk assessment model for biomarker research, clinical pilot programs, or method development.
Structured risk reports from metabolomics data
Full validation methodology and data requirements
Collaborate with our team on your studies
All fields marked * are required
Prefer email? Contact us directly at [email protected]